Thomas L. Holland

Thomas L. Holland, an infectious disease specialist and professor at Duke University, discusses the innovative treatment of complicated Staphylococcus aureus bacteremia using Dalbavancin. He shares insights from the groundbreaking DOTS trial, which compares this long-acting antibiotic to traditional IV therapies, highlighting its potential to improve patient outcomes and quality of life. The conversation also addresses challenges in treatment, particularly for vulnerable populations, and the urgency of developing safer options for this serious infection.

In this insightful conversation, Thomas L. Holland, an infectious disease specialist at Duke University, delves into the challenges of treating complicated Staphylococcus aureus bacteremia. He discusses the promising results of the DOTS trial, which evaluates dalbavancin as a long-acting treatment option that may eliminate the need for prolonged IV access. Holland and host Preeti Malani explore the significance of the Desirability of Outcome Ranking in clinical trials and the surprising similarities in quality of life outcomes between different treatment approaches.